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ABSTRACT 1 
Introduction:  2 
We previously showed, in patients with diabetes, that >50% of monitoring tests for glycated 3 
hemoglobin (HbA1c) are outside recommended intervals and that this is linked to diabetes 4 
control. Here, we examined the impact of tests/year on achievement of commonly-utilised 5 
HbA1c targets and on HbA1c changes over time. 6 
Subjects & Methods:  7 
Data on 20,690 adults with diabetes with a baseline HbA1c of >53 mmol/mol (7%) were 8 
extracted from Clinical Biochemistry Laboratory records at three UK hospitals. We examined 9 
the impact of HbA1c tests/year on: (i) probability of achieving targets of ≤53mmol/mol (7%) 10 
and ≤48mmol/mol (6.5%) in a year using multi-state modelling and (ii) changes in mean 11 
HbA1c using a linear mixed-effects model.  12 
Results:  13 
The probabilities of achieving ≤53mmol/mol (7%) and ≤48mmol/mol (6.5%) targets within 1 14 
year were 0.20 (95% confidence interval:0.19-0.21) and 0.10 (0.09-0.10), respectively. 15 
Compared with 4 tests/year, having 1 test or >4 tests/year were associated with lower 16 
likelihoods of achieving either target; 2-3 tests/year gave similar likelihoods to 4 tests/year. 17 
Mean HbA1c levels were higher in patients who had 1 test/year compared to those with 4 18 
tests/year (mean difference: 2.64mmol/mol [0.24%], p<0.001). 19 
Conclusions:  20 
4 
 
We showed that ≥80% of patients with sub-optimal control are not achieving commonly 1 
recommended HbA1c targets within 1 year, highlighting the major challenge facing 2 
healthcare services. We also demonstrated that, while appropriate monitoring frequency is 3 
important, 6-monthly testing is as effective as quarterly testing, supporting international 4 
recommendations. We suggest that the importance HbA1c monitoring frequency is being 5 
insufficiently recognised in diabetes management.  6 
5 
 
INTRODUCTION 1 
Achieving and maintaining adequate glycaemic control, as measured by glycated 2 
hemoglobin (HbA1c), is the focus of management strategies for patients with diabetes 3 
mellitus (DM). Guidance from many professional bodies worldwide recommends regular 4 
HbA1c monitoring to optimise the chances of attaining treatment goals for these patients. 5 
American Diabetes Association guidelines recommend testing ‘at least two times a year in 6 
patients who are meeting treatment goals (and who have stable glycemic control)’ and 7 
‘quarterly in patients whose therapy has changed or who are not meeting glycaemic goals’ 8 
(1), while UK National Institute for Health and Care Excellence (NICE) guidance recommends 9 
measuring HbA1c at ‘3–6-monthly intervals…, until the HbA1c is stable on unchanging 10 
therapy’ and ‘6-monthly intervals once the HbA1c level and blood glucose lowering therapy 11 
are stable’ (2-3). 12 
 13 
While guidance on monitoring frequency is clear, studies have shown that many patients do 14 
not have tests at the recommended frequency (4-11). For example, a Australian study (10) 15 
showed that, of patients with HbA1c >53 mmol/mol (>7%), only 22.9% received a follow-up 16 
test within the recommended 3-monthly interval over the 24 month study period, while we 17 
showed that >50% of all tests are requested outside recommended monitoring intervals 18 
(21% too soon; 30% too late) (7). We have observed this phenomenon in other cases where 19 
scheduled testing is required (12). This raises questions as to the implications of inadequate, 20 
excessive or inappropriate monitoring, on both clinical and economic endpoints (11). In an 21 
attempt to provide some validation of recommended intervals, Parcero et al (13), in a study 22 
of 193 patients with diabetes in general practice, found that median HbA1c values in 23 
patients who were tested at recommended intervals were significantly lower than those in 24 
6 
 
patients with intervals that did not adhere to guidelines. Furthermore, we have previously 1 
shown that HbA1c monitoring interval is associated with changes in diabetes control, as 2 
measured by difference in HbA1c levels between consecutive tests (11) while Phan et al (14) 3 
showed that excessive or infrequent testing was associated with a higher proportion of 4 
patients with worsening glycaemic control. Fu et al (15) also studied the relationship 5 
between patient-reported HbA1c testing frequency and optimal glycaemic control defined 6 
as a target HbA1c of <53 mmol/mol (<7%). They showed that, after adjusting for age, 7 
gender, education level and lifestyle factors, patients with ≥2 tests/year were more likely to 8 
have an HbA1c below target than those with either one or no tests during that period. 9 
 10 
With regard to patient management, the most important decision is how frequently to test 11 
in order to achieve the patient treatment goal. While Fu et al (15) sought to address this, 12 
their analysis was cross-sectional and did not sub-classify patients with ≥2 tests/year. Loh et 13 
al (16) indicated that testing more frequently than every 4 weeks was not justified while 14 
Phan et al (14) indicated that, in young patients with type 1 diabetes, four tests/year was 15 
least likely to result in worsening control. Nevertheless, the wider question of optimum 16 
number of test/year to attain the target HbA1c remains elusive.  17 
 18 
In this study, we hypothesised that requesting HbA1c tests at recommended frequcny 19 
would result in a higher proportion achieving target and reduced overall HbA1c levels within 20 
1 year. We analysed four years of HbA1c records from a cohort of patients with HbA1c levels 21 
>53 mmol/mol (7%) at baseline from a dataset of 39,138 patients with DM across three UK 22 
centres. We developed dynamic modelling based on multistate models to examine the 23 
impact of number of tests/year on the probability of achieving targets of 53 mmol/mol (7%) 24 
7 
 
and 48 mmol/mol (6.5%), as suggested in most guidance (1-3). Additionally, we examined 1 
the impact of frequency of testing on HbA1c levels over the course of the 4 years using 2 
longitudinal modelling.  3 
8 
 
RESEARCH DESIGN AND METHODS 1 
Patients 2 
This study involved patient level data collected as part of routine clinical practice from 3 
clinical laboratory databases.  Data on all HbA1c test requests from 39,138 patients >16 4 
years old collected from 2007 to 2011 were extracted from the Clinical Biochemistry 5 
Laboratory Information Management Systems at the University Hospital of North Midlands 6 
NHS Trust (UHNM), Royal Wolverhampton NHS Trust (RWT) and Salford Royal NHS 7 
Foundation Trust (SRFT) (7,11). HbA1c concentrations were obtained using either cation-8 
exchange high performance liquid chromatography (Tosoh G8; UHNM and RWT) or borate 9 
affinity high performance liquid chromatography (Menarini Hb9210; SRFT) methodology, 10 
with a between batch coefficient of variation of <2%. In each laboratory, external quality 11 
assurance was provided by membership of the UK National External Quality Assurance 12 
Scheme (NEQAS). From this data set, we examined the cohort of patients who had a 13 
baseline HbA1c test above 53 mmol/mol (7%) and at least one further HbA1c requested on 14 
an annual anniversary (i.e. at intervals of 365 days ± 30 days) during the study period. These 15 
comprised 20,836 individuals, 53.2% of the original dataset; 146 were excluded due to 16 
missing HbA1c levels. This left a core dataset of 20,690 participants (3483 from SRFT, 9502 17 
from UHNM and 7705 from RWT), including information on dates of requested tests in the 18 
course of four years, HbA1c levels, age, sex and centre. 19 
 20 
Model development and study design 21 
Rates of transition and probability of achieving HbA1c targetThe main objective was to 22 
examine the impact of frequency of testing on the probability of achieving a target HbA1c 23 
level (≤53 mmol/mol [≤7%] or ≤48 mmol/mol [≤6.5%]) for patients with sub-optimal control 24 
9 
 
at baseline. Each patient had 1-4 HbA1c records on the annual anniversaries after baseline. 1 
For each patient, at each of their yearly test dates, we defined two possible states: “HbA1c 2 
level >target”, if the HbA1c level was above the set threshold, or “HbA1c level ≤target” if the 3 
target was achieved.  Every patient occupied the “HbA1c level >target” state (for the 53 4 
mmol/mol [7%] threshold) at baseline. Over time, at each yearly test request, a patient 5 
either remained in their current state or moved to the other state, generating a sequence of 6 
transitions from one state to the other. A multi-state model (17) was developed, for each 7 
threshold value (53 mmol/mol [7%] and 48 mmol/mol [6.5%]), to model these transitions. 8 
 9 
A time-varying categorical variable “frequency of testing” was created to indicate the 10 
number of tests a patient had within his/her previous year’s record (excluding the baseline 11 
test), with value “1” if the patient had just one additional test, “2”, “3”, “4” and “>4” if the 12 
patient had 2, 3, 4, or 5 or more additional tests, respectively. 13 
 14 
The hazard functions of transition were modelled in terms of frequency of testing, sex, age 15 
and centre. In addition, the model was stratified by baseline HbA1c category (53-64, 64-75, 16 
75-86,86-108,>108 mmol/mol [7-8%, 8-9%, 9-10%, 10-12% >12%]) to give an indication of 17 
the initial degree of sub-optimal control. 18 
  19 
The focus of the analysis was the rate of transition from “HbA1c level >target” to “HbA1c 20 
level ≤target”; this provides a dynamic assessment of glycaemic control. Estimates of the 21 
hazard ratios are reported for each explanatory variable.  For a categorical variable (e.g. 22 
frequency of testing), the hazard ratio represents the ratio of transition rates for each 23 
category compared to a reference category. For a continuous variable (e.g. age), the hazard 24 
10 
 
ratio is the ratio of transition rates for two individuals with one unit difference. A hazard 1 
ratio value of one indicates no difference in rates.  Finally, from this model the probability of 2 
moving from the state “HbA1c level >target” to the state “HbA1c level ≤target” during one 3 
year was calculated overall and by frequency of testing, holding the values of other 4 
explanatory variables fixed at their mean value. 5 
 6 
Changes of HbA1c levels over time 7 
The second objective was to assess the impact of frequency of testing on changes in HbA1c 8 
levels over time. A linear mixed-effects regression model with a random intercept was fitted 9 
to HbA1c levels, after screening of the sampling distribution of the data to check that the 10 
distribution was symmetric. The linear regression model included frequency of testing, sex, 11 
age (centred on the baseline mean), centre, a categorical variable for time from baseline as 12 
explanatory variables and a random intercept. A quadratic term for age was also included to 13 
assess departures from the assumption of linearity between HbA1c levels and age.  14 
 15 
 16 
Statistical analysis 17 
As described above, the impact of frequency of testing on the probability of achieving a 18 
target HbA1c level (≤53 mmol/mol [≤7%] or ≤48 mmol/mol [≤6.5%]) for patients with sub-19 
optimal control at baseline was analysed using multi-state model for each target.  A linear 20 
mixed-effects regression model with a random intercept was used to assess impact of 21 
testing frequency on HbA1c levels. All models were fitted by maximum likelihood 22 
estimation. P-values for the linear random effects model were calculated using Wald tests. 23 
11 
 
All analyses were performed using the statistical software R (18) with the packages “msm” 1 
(19) and “lme4” (20). 2 
  3 
12 
 
RESULTS 1 
Descriptive statistics 2 
The cohort of 20,690 patients (55.9% male) had a median age of 62 years (IQR=51-71 years) 3 
and a median HbA1c concentration of 65 mmol/mol (IQR=57.4-79.2 mmol/mol; 8.1%,  4 
IQR=7.4-9.4%) at baseline. Of these, 11,872 patients contributed data at baseline and 1 5 
year, 5952 with an additional year, 2187 with 3 years and 572 with 4 consecutive years after 6 
baseline. The remaining 107 cases contributed data at baseline and other combinations of 7 
years (eg 22 cases contributed data at baseline, and years 1 and 3). 8 
 9 
In the course of the four years, in only 20.4% (6137/30,054) of instances did the HbA1c level 10 
change from >53 mmol/mol (>7%l; above target) to ≤53 mmol/mol (≤7%; below target) 11 
between two consecutive years. Changes from HbA1c >48 mmol/mol (>6.5%) to HbA1c ≤48 12 
mmol/mol (≤6.5%) were observed in only 10.0% (3139/31,540) of occasions. 13 
 14 
The boxplots in Supplemental Figure S1 show the empirical distribution of HbA1c levels by 15 
frequency of testing. Although this does not account for the correlation among observations 16 
from the same individual or the effect of time, it is apparent that the overall HbA1c levels 17 
were similar across the groups. 18 
 19 
Rates of transition and probability of achieving HbA1c target 20 
Table 1 shows the hazard ratio estimates of a transition from HbA1c >target to HbA1c 21 
≤target. There was no difference in rates of achieving either target between females and 22 
males. However, the hazard ratio for age was greater than one, indicating that older 23 
patients are more likely to achieve target. There were also differences between centres, 24 
13 
 
with cases from RWT more likely to achieve the 53 mmol/mol (7%) target, and those from 1 
both UHNM and RWT less likely to achieve the 48 mmol/mol (6.5%) target relative to SRFT. 2 
As expected, cases with a higher baseline HbA1c were less likely to achieve the targets 3 
compared with those with an initial HbA1c of 53-64 mmol/mol (7-8%), though those with a 4 
baseline HbA1c of >108 mmol/mol (>12%) were generally more likely to achieve target than 5 
those with values between 64 and 108 mmol/mol (8-12%). 6 
 7 
As most guidelines on frequency of monitoring for sub-optimally controlled patients 8 
recommend 4 tests/year, this was chosen as comparator (reference category) in assessment 9 
of impact of testing frequency on achievement of target. The proportion achieving either 53 10 
mmol/mol (7%) or 48 mmol/mol (6.5%) targets were similar for those patients who were 11 
monitored twice or three times a year, to those the reference category (4 tests/year). In 12 
contrast, compared with 4 tests/year, there was a 33% and 25% decrease in the rates of 13 
achieving the 53 mmol/mol (7%) target for monitoring frequencies of 1 and >4 times/year, 14 
respectively. Similarly, those who were monitored 1, or >4 times had a 39% and 20% 15 
reduction in the rates of achieving the 48 mmol/mol target, respectively.  16 
 17 
Table 2 shows the estimated probability of each possible transition, holding the explanatory 18 
variables fixed at their mean value. The overall probability of achieving the 53 mmol/mol 19 
(7%) target for patients who were sub-optimally controlled the previous year was 0.20 (95% 20 
CI: 0.19, 0.21), and 0.10 (95% CI: 0.09, 0.10) for the 6.5% (48 mmol/mol) threshold. Thus, 21 
only 20% of cases were predicted to achieve the 53 mmol/mol (7%) target. Furthermore, 22 
once this target was achieved, 52% of cases were predicted to remain within target in the 23 
14 
 
subsequent year. Similarly, for the 48 mmol/mol (6.5%) target, only 10% were predicted to 1 
achieve target and 52% predicted to subsequently remain within this target.` 2 
 3 
Figure 1 provides a graphical representation of the probability of achieving the HbA1c target 4 
in one year overall and by frequency of testing. The probability of achieving the target is 5 
comparable when 2 or 3 tests are done compared to 4 for both thresholds. However, both 1 6 
test/ year and >4 tests/year had a lower probability of achieving either target. 7 
 8 
Changes of HbA1c levels over time 9 
Table 3 shows the estimated mean changes in HbA1c level over time from a linear mixed-10 
effects model. There was no significant difference in mean HbA1c level between males and 11 
females, or between sites. However, there was a non-linear relationship between mean 12 
HbA1c values and age, as reflected by the statistical significance of both linear and quadratic 13 
terms.  This relationship is illustrated in Supplemental Figure S2. It shows that HbA1c levels 14 
were higher in younger patients, but this year-on-year decrease in mean HbA1c levels 15 
becomes smaller with increasing age. Table 3 also shows the mean differences in HbA1c 16 
levels over time. This illustrates that the mean HbA1c did not change significantly during the 17 
course of the study, except in the last year where there was a statistically significant 18 
increase of 1.42 mmol/mol (0.13%) with respect to year 1. This may reflect overall disease 19 
progression over time. 20 
 21 
There was no significant difference in mean HbA1c levels with 2 or 3 tests/year compared 22 
with 4 tests/year. However, there was a significant mean difference in HbA1c levels of 2.64 23 
mmol/mol (95% CI: 2.00, 3.28) (0.242%, 95% CI: 0.183, 0.300) between those who have 1 24 
15 
 
and those who have 4 tests/year. Those who had >4 tests also had a slightly larger value 1 
than the reference group (those with 4 tests); mean difference was 0.52 mmol/mol (95% CI: 2 
-0.001, 1.03) (0.048%, 95% CI: 0.000, 0.095).  3 
16 
 
DISCUSSION 1 
We demonstrated, using dynamic modelling, in a large cohort of sub-optimally controlled 2 
patients with diabetes across three UK centres, that (i) 80% of patients fail to achieve a 3 
target of ≤53 mmol/mol (≤7%) within 1 year (90% fail to achieve a target of ≤48 mmol/mol 4 
(≤6.5%)), and (ii) overall, two or three HbA1c tests/year are equivalent to four tests at 5 
achieving HbA1c target values, but one test per year was inadequate; there was no added 6 
benefit in carrying out more than four HbA1c tests/year. 7 
 8 
Rates of transition and probability of achieving HbA1c target 9 
Overall probability of achieving targets. The large number of patients with sub-optimal 10 
control who do not reach recommended targets, despite regular monitoring, is of major 11 
concern. Our findings that only ~20% of patients with HbA1c >53 mmol/mol (>7%) attain a 12 
target level of ≤53 mmol/mol (≤7%) one year later are similar to the 32% seen by Anichini et 13 
al (21) in a small cross-sectional sample (n=315) with a similar baseline (72.7 mmol/mol 14 
[8.8%]) and 1-year (58.5 mmol/mol [7.5%]) HbA1c values. In the study by Paul et al (10), 15 
only 18.5% of cases with a baseline HbA1c of >53 mmol/mol (>7%) had a subsequent test 16 
result below 53 mmol/mol (7%) over the 2 year follow-up period. Hence, in spite of the 17 
resources put into diabetes management, many patients remain above target HbA1c, with 18 
all the attendant adverse long-term health consequences for the individual (22-24). 19 
 20 
Impact of monitoring frequency. Our analysis then focussed on assessment of the impact of 21 
monitoring frequency on the rate of transitions from sub-optimal to target glycaemic 22 
control. Our multistate model accommodated the adjustment to monitoring frequency that 23 
is likely to occur, for a given patient, following a high HbA1c measurement, thus providing a 24 
17 
 
dynamic assessment of glycaemic control. Our results clearly show that annual testing is 1 
inadequate, yielding a 33% reduced likelihood of achieving control compared to 4 2 
tests/year.  3 
 4 
Our data is consistent with the work of Fu et al (15) in 1511 patients with type 2 diabetes 5 
attending outpatient clinics, where they identified that two or more tests/year resulted in a 6 
higher proportion of patients having a HbA1c of <53mmol/mol (<7%) (26.8%) compared 7 
with those who had one test/year (24.8%). However, our analysis extends this in indicating 8 
that more than 3-4 tests/year offers limited additional benefit in this regard, while >4 9 
tests/year resulted in a reduced probability of achieving target. This is largely in keeping 10 
with recommended monitoring frequency in most international guidance (1-3) and with our 11 
previous work (11), though our data more explicitly support the view  that 2-3 times per 12 
year is equally as effective as 4 times per year in achieving commonly used targets in sub-13 
optimally controlled diabetes patients. Importantly, our findings appeared important 14 
relative to other factors, suggesting that monitoring interval is worthy of further attention in 15 
considering opportunities to intervene in order to achieve the recommended target.  16 
 17 
While there were no differences in the rates of transition to optimal control between male 18 
and female patients, there was a small increase in the likelihood of achieving optimal 19 
control for older patients. This may relate to the observation that HbA1c values tended to 20 
be lower for older patients (-0.27 mmol/mol per year difference in age; Supplemental Figure 21 
S2). These findings are consistent with findings in a systematic review by Mannicci et al 22 
which showed that older age was associated with a higher success rate for achieving targets 23 
in both type 1 and type 2 DM (26). The CREDIT study demonstrated that younger age was 24 
18 
 
associated with being above the 53 mmol/mol (7.0%) HbA1c target (27) after correction for 1 
a range of other covariates. This may indicate that (i) older people may be better equipped 2 
to take charge of their diabetes, (ii) prevalence of anaemia increases with age and this may 3 
result in generally lower overall HbA1c levels due to more rapid red cell turnover (28, 29), 4 
and/or (iii) with more effective screening in primary care, a proportion of less complex cases 5 
are being diagnosed with T2DM (who would have lower HbA1c value and therefore 6 
potentially attain targets more readily). As expected, individuals with lower baseline HbA1c 7 
levels were more likely to achieve target. Those with initial HbA1c value 64-75 mmol/mol (8-8 
9%) were 51% less likely to achieve the target than those with 53-64 mmol/mol (7-8%). 9 
However, those with a baseline value (108 mmol/mol (>12%) were only 35% less likely. This 10 
may be a consequence of more active intervention within this group, including secondary 11 
care and specialist nursing/dietetic input.   12 
 13 
Changes of HbA1c levels over time 14 
The longitudinal analysis on the relationship between tests/year and change in HbA1c was 15 
generally consistent with findings from the dynamic moddelling analysis. This showed that 16 
one test/year results in, on average, an increase in HbA1c of 2.64 mmol/mol (0.24%) 17 
compared with 4 tests/year. Extrapolating from UKPDS data (25), this would equate to a 18 
difference in risk of 5% for diabetes-related deaths, 3% for myocardial infarction, 3% for 19 
stroke, 4% for heart failure and 9% for microvascular complications.  20 
 21 
Strengths and limitations 22 
While this study indicates the overall optimum testing frequency in order to achieve 23 
commonly used targets in a large cohort across three centres using dynamic modelling, we 24 
19 
 
recognise that there are limitations to the study. Laboratory records provide limited access 1 
to clinical data and we were therefore unable to explore other factors such as the 2 
differentiation between type 1 and type 2 diabetes (or gestational diabetes), or 3 
treatment/lifestyle interventions which may influence the frequency of monitoring and 4 
rates of achieving targets. Neither did we explore the reasons lack of monitoring; a topic 5 
that has been examined elsewhere (30-33) and was beyond the scope of this study. We 6 
restricted the analysis to patients with sub-optimally controlled diabetes, so results cannot 7 
be generalised to the whole population of patients with diabetes. We also recognise that 8 
guidance suggests agreeing specific treatment targets for individual patients and so our 9 
definition of the cut-off for optimal control (<53mmol/mol (<7%)) could be perceived as an 10 
over-generalisation. However, our results indicate that testing frequency is important, a 11 
finding that is of particular concern following previous work showing that many patients do 12 
not have tests at the recommended intervals (4-10). 13 
To our knowledge, this study is the first to provide a dynamic assessment of glycaemic 14 
control. This was achieved by modelling a patient’s rate of transition within a year, from 15 
sub-optimal to optimal control, as a function of frequency of HbA1c testing the previous 16 
year, patient characteristics and centre. In contrast, previous observational studies are 17 
limited in their use of a single post-baseline HbA1c measurement (or average of a few 18 
follow-up measurements) in standard logistic regression analysis to estimate the probability 19 
of achieving glycaemic control post-baseline. 20 
 21 
As distinct from other studies, we did not stratify by baseline HbA1c. Such stratification has 22 
been attempted in previous observational cross-sectional studies by adjusting for the 23 
baseline HbA1c in linear or logistic regression analysis of a post-baseline HbA1c 24 
20 
 
measurement (e.g. 21, 34). Although it may seem sensible to adjust for the baseline value 1 
because this is likely to predict the post-baseline HbA1c measurement, it has been shown 2 
(35, 36) that adjusting for the baseline value in observational studies, may introduce bias 3 
into the estimates of the effect of an exposure (frequency of testing in the present context). 4 
 5 
Overall conclusions 6 
While our findings highlight the importance of HbA1c monitoring frequency as well as levels 7 
in facilitating achievement of targets, we recognise that improvements in monitoring would 8 
not, in themselves, address the fact that a very large proportion of patients are not 9 
achieving target within one year. This remains a major challenge for healthcare services and 10 
indeed the wider social environment. It also highlights the need for behavioural change in 11 
facilitating appropriate HbA1c monitoring in diabetes (1-3, 5, 7, 10) as well as in a range of 12 
other patient groups (12, 33). 13 
 14 
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Table 1  Estimated hazard rates (95% CI) for the transitions from HbA1c >target to 1 
HbA1c ≤target 2 
 3 
Explanatory 
Transition 
  
 variable  HbA1c >53 mmol/mol to 
HbA1c ≤53mmol/mol 
(>7% to ≤7%) 
HbA1c >48  mmol/mol to 
HbA1c ≤48 mmol/mol 
(>6.5% to ≤6.5%) 
Sex     
Female Reference Reference 
Male   0.98, (0.83, 1.16) 0.96, (0.86, 1.08) 
   
Age 1.01, (1.00, 1.01) 1.00, (1.00, 1.01) 
   
Frequency of tests     
4 Reference Reference 
1 0.67, (0.56, 0.80) 0.61, (0.49, 0.77) 
2 0.88, (0.75, 1.03) 0.92, (0.75, 1.11) 
3 0.98, (0.83, 1.16) 1.00, (0.81, 1.23) 
> 4  0.75, (0.62, 0.91) 0.80, (0.63, 1.02) 
   
Baseline HbA1c 
 
  
53-64 mmol/mol (7-8% ) Reference Reference 
64-75 mmol/mol (8-9%) 0.49, (0.40, 0.51) 0.55, (0.47, 0.64) 
75-86 mmol/mol (9-10%) 0.37, (0.31, 0.43) 0.50, (0.42, 0.61) 
86-108 mmol/mol (10-12%) 0.38, (0.32, 0.44) 0.53, (0.44, 0.65) 
>108 mmol/mol (>12%) 0.65, (0.50, 0.83) 0.84, (0.63, 1.13) 
   
Site     
SRFT Reference Reference 
UHNM 1.12, (0.99, 1.27) 0.81, (0.70, 0.95) 
RWT 1.23, (1.08, 1.40) 0.85, (0.72, 1.00) 
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Table 2  Estimated probabilities (95%CI) of each transition in one year, holding the 1 
explanatory variables in the model (see Table 1) fixed on their mean values. For example, 2 
the probabilities of achieving targets of ≤53 mmol/mol (7%) and ≤48 mmol/mol (6.5%), with 3 
a starting point of >53mmol/mol (>7%), are presented in bold. Similarly, the probabilities of 4 
remaining below a target of ≤53 mmol/mol (7%), once achieved, are presented in italics. 5 
 6 
  Year t 
 
HbA1c ≤53 mmol/mol 
(≤7%) 
HbA1c >53 mmol/mol 
(>7%) 
Year t-1   
HbA1c >53 mmol/mol (>7%) 0.20 (0.19, 0.21) 0.80 (0.79, 0.81) 
   
HbA1c ≤53 mmol/mol (≤7%) 0.52 (0.48, 0.55) 0.48 (0.45, 0.52) 
  Year t 
 
HbA1c ≤48 mmol/mol 
(≤6.5%) 
HbA1c >48 mmol/mol 
(>6.5%) 
Year t-1   
HbA1c >48 mmol/mol (>6.5%) 0.10 (0.09, 0.10) 0.90 (0.90, 0.91) 
   
HbA1c ≤48 mmol/mol (≤6.5%) 0.52 (0.48, 0.55) 0.48 (0.45, 0.52) 
  7 
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Table 3  Estimated mean differences from linear random effects model for HbA1c 1 
levels. 2 
 3 
Explanatory variable Mean difference in HbA1c levels (95% CI) P-value 
 (mmol/mol) (%)   
Sex    
Female Reference Reference   
Male   -0.11 (-0.55, 0.34) -0.010 (-0.050, 0.032) 0.63 
                   
Age     
Linear term     -0.27 (-0.29, -0.25) -0.025 (-0.026, -0.023) < 0.001       
Quadratic term 0.003 (0.002, 0.004) 0.0003 (0.0002, 0.0003) < 0.001       
                   
Frequency of tests     
4 Reference Reference   
1 2.64 (2.00, 3.28) 0.242 (0.183, 0.300) < 0.001       
2 0.39 (-0.12, 0.90) 0.036 (-0.011, 0.083) 0.14 
3 0.05 (-0.47, 0.57) 0.005 (-0.043, 0.052) 0.85 
> 4  0.52 (-0.001, 1.03) 0.047 (-0.0001, 0.094) 0.05 
                   
Site     
SRFT Reference Reference   
UHNM 0.16 (-0.47, 0.79) 0.015 (-0.043, 0.072) 0.62 
RWT 0.26 (-0.39, 0.91) 0.024 (-0.036, 0.083) 0.43 
      
Year     
Year 1 Reference Reference   
Year 2 -0.06 (-0.37, 0.24) -0.006 (-0.033, 0.022) 0.69 
Year 3 0.39 (-0.10, 0.88) 0.036 (-0.009, 0.081) 0.12 
Year 4 1.42 (0.41, 2.43) 0.130 (0.038, 0.222) 0.01 
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Figure 1 Probability of transition HbA1c >target to HbA1c ≤target (95% CI); overall 1 
and by number of tests per year holding the values of other explanatory variables in the 2 
model (Table 1) fixed on their mean value. 3 
 4 
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Supplemental Figure S1  Boxplots of HbA1c levels by number of tests per year 1 
2 
  3 
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Supplemental Figure S2  Predicted HbA1c levels by age, with 95% confidence band 1 
 2 
